Aralez Pharmaceuticals Inc. (ARLZ)
The company's stock has fell -10.47 percent in the past five year.
Chardan Capital bumped down the target of Aralez Pharma (NASDAQ:ARLZ) to $5.50 stating a potential upside of 1.63%.
On 5/20/2016 James Patrick Tursi, Insider, bought 10,000 with an average share price of $3.75 per share and the total transaction amounting to $37,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Aralez Pharmaceuticals expects full-year revenue in the range of $80 million to $100 million. The company has experienced volume of 6,241,062 shares while on average the company has a capacity of trading 668.73K share.
Aralez Pharmaceuticals Inc. - Common Shares (ARLZ) made into the market gainers list on Wednesdays trading session with the shares advancing 13.40% or 0.28 points. Hold - In general terms, a company with a hold recommendation is expected to perform at the same pace as comparable companies or in-line with the market.
Aralez Pharmaceuticals Inc. NASDAQ:ARLZ performance during the last one year Degraded -58.66 percent, while its year to date (YTD) performance showed a Negative trend of -44.22 percent. Two equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $11.13. The company had revenue of $20 million for the quarter, compared to analysts' expectations of $21.86 million. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The stock is up 43.31% in this year through last close.
Analysts estimated $-0.26/share for the previous Quarter, where Aralez Pharmaceuticals Inc. Full-year profit views are for Aralez Pharmaceuticals Inc.to earn -$1.47 in current year and drop profits by almost 444.44% over last year's earnings of -$0.27.
On Wednesday February 10, 2016, Guggenheim released a statement on Aralez Pharma (NASDAQ:ARLZ) bumped up the target price from $0.00 to $12.00. About 3.37 million shares traded or 287.47% up from the average. LLC boosted its position in shares of Aralez Pharmaceuticals by 30.3% in the third quarter.
The stock showed weekly upbeat performance of 0.51%, which maintained for the month at -2.19%. Integre Asset Management LLC raised its position in shares of Aralez Pharmaceuticals by 31.7% in the fourth quarter.
Shares opened 19% down on Monday at US$2.84. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aralez Pharmaceuticals during the fourth quarter valued at about $103,000. The firm has "Buy" rating by Canaccord Genuity given on Tuesday, April 26.
The increase in SG&A expenses was primarily driven by increased commercialization costs incurred in the US, predominantly related to the launch of Yosprala in October 2016, costs to support the build out of the Aralez global corporate structure, continuing operational expenses in Canada, product acquisition-related expenses and higher share based compensation expenses. The Firm focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas.